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Running title: COPD impairs mROS mediated bacterial killing 37 
Descriptor Number: 10.9 Pathogen/Host cell interactions 38 
Total word count: 3442 39 
At a glance summary: 40 
Scientific Knowledge on the Subject: COPD patients are at increased risk from 41 
bacterial respiratory infections, which cause acute exacerbations adding to morbidity. 42 
Previous studies have identified potential defects in innate immunity but the effect of 43 
COPD on macrophage microbicidal responses has been little investigated. Host-44 
mediated macrophage apoptosis in response to bacteria gives an increment to bacterial 45 
killing once canonical phagolysosomal killing has become exhausted. Defects in this 46 
pathway alter bacterial clearance. 47 
 1 
What This Study Adds to the Field: We show that inhibition of macrophage apoptosis 1 
and a failure to induce mitochondrial reactive oxygen species generation in COPD 2 
macrophages contributes to impaired clearance of pneumococci in the lung.  3 
Footnote: 4 
3UHVHQWHG LQ SDUW DV ³$OYHRODU PDFURSKDJHV GXULQJ &23' GHPRQVWUDWH UHGXFHG5 
apoptosis-associated bacterial killing and reduced mitochondrial reactive oxygen 6 
species-GHSHQGHQWNLOOLQJ´0%HZOH\5%XGG'6LQJK3-%DUQHVL.E. Donnelly, 7 
M.K.B. Whyte, D.H. Dockrell, Medical Research Council COPD MAP Consortium. 8 
American Thoracic Society International Conference San Diego May 19th, 2014. Am J. 9 
Respir Crit Care Med 18:2014; A2862  10 
 2 
Abstract: 1 
 2 
Rationale: Chronic obstructive pulmonary disease (COPD) is characterized by impaired 3 
clearance of pulmonary bacteria.  4 
Objectives: The effect of COPD on alveolar macrophage (AM) microbicidal responses 5 
was investigated. 6 
Methods: Alveolar macrophages (AMs) were obtained from bronchoalveolar lavage 7 
from healthy donors or COPD patients and challenged with opsonized serotype 14 8 
Streptococcus pneumoniae. Cells were assessed for apoptosis, bactericidal activity and 9 
mitochondrial reactive oxygen species (mROS) production. A transgenic mouse line, in 10 
which the CD68 promoter ensures macrophage specific expression of human Mcl-1 11 
(CD68.hMcl-1), was used to model the molecular aspects of COPD.  12 
Measurements and Main Results: COPD AM had elevated levels of Mcl-1, an anti-13 
apoptotic Bcl-2 family member, with selective reduction of delayed intracellular 14 
bacterial killing. CD68.hMcl-1 AM phenocopied the microbicidal defect since 15 
transgenic mice demonstrated impaired clearance of pulmonary bacteria and increased 16 
neutrophilic inflammation. Murine bone marrow-derived macrophages (BMDM) and 17 
human monocyte-derived macrophages (MDM) generated mitochondrial reactive 18 
oxygen species (mROS) in response to pneumococci, which co-localized with bacteria 19 
and phagolysosomes to enhance bacterial killing. The Mcl-1 transgene increased oxygen 20 
consumption rates and mROS expression in mock-infected BMDM but reduced caspase-21 
dependent mROS production after pneumococcal challenge. COPD AM also increased 22 
basal mROS expression, but failed to increase production after pneumococcal challenge, 23 
in keeping with reduced intracellular bacterial killing. The defect in COPD AM 24 
intracellular killing was associated with a reduced ratio of mROS /superoxide dismutase 25 
2.  26 
 3 
Conclusions: Upregulation of Mcl-1 and chronic adaption to oxidative stress alters 1 
mitochondrial metabolism and microbicidal function, reducing the delayed phase of 2 
intracellular bacterial clearance in COPD.  3 
 4 
Word count: 250 5 
Key words: Apoptosis, mitochondrial reactive oxygen species, Streptococcus 6 
pneumoniae.  7 
 4 
Introduction  1 
Chronic obstructive pulmonary disease (COPD) is characterized by incompletely 2 
reversible airway obstruction. Neutrophilic inflammation drives airway narrowing and 3 
alveolar destruction (1). Cigarette smoke and biomass fuels are major factors initiating 4 
COPD pathogenesis and persistent neutrophilic inflammation in those who quit smoking 5 
emphasizes the importance of additional etiologic factors in maintaining progressive 6 
airway destruction (2, 3).  7 
 8 
Clinical exacerbations of COPD, punctuate periods of relative stability in many patients, 9 
and contribute to the decline in respiratory function (4). Exacerbations are frequently 10 
associated with the presence of pathogenic bacteria in the lower airway and the lower 11 
airway bacterial load correlates with markers of neutrophilic inflammation such as 12 
CXCL8 levels (5). This suggests that a key driver of COPD pathogenesis is a defect in 13 
airway innate immune responses to pathogenic bacteria. While Haemophilus influenzae, 14 
Streptococcus pneumoniae and Moraxella catarrhalis are all associated with infective 15 
exacerbations, S. pneumoniae remains the major cause of community-acquired 16 
pneumonia (CAP) in COPD (6, 7). The relative risk of CAP, pneumococcal CAP and 17 
invasive pneumococcal disease (IPD) is elevated in patients with COPD to a greater 18 
extent than smokers another group at increased risk of IPD (8). This suggests that 19 
patients with COPD possess significant defects in their host defences to pneumococcal 20 
disease in the lower airway. However the basis of this increased susceptibility to 21 
pneumococcal pneumonia remains undefined. 22 
 23 
Alveolar macrophages (AM) are central to the organization of pulmonary innate 24 
immunity and are critical for clearance of pneumococci from the alveolar space (9).  25 
However, AM do not possess several of the microbicidal molecules used by neutrophils 26 
 5 
and pathogens have acquired adaptions to resist others (10), which challenges AM 1 
microbicidal capacity.  Macrophages therefore employ additional host defence strategies 2 
and induction of apoptosis is required for efficient clearance of intracellular bacteria 3 
after phagocytosis (9, 11). Apoptosis is controlled by expression of the anti-apoptotic 4 
protein Mcl-1, which is dynamically regulated after bacteria are internalized (12, 13). 5 
COPD is associated with decreased macrophage innate competence as illustrated by 6 
evidence for impaired bacterial phagocytosis of non-typeable H. influenzae and S. 7 
pneumoniae, the pathogens that most frequently colonize the lower airway in COPD (14, 8 
15). Little is known, however, concerning the effect of COPD on AM microbicidal 9 
responses. 10 
 11 
We observed that COPD AM have persistent upregulation of Mcl-1 and have used 12 
patient AM and a unique murine transgenic macrophage to test how Mcl-1 upregulation 13 
alters pulmonary antibacterial host defense. Specifically, we addressed how Mcl-1 14 
influenced macrophages ability to generate a mitochondrial microbicidal response 15 
involving generation of mitochondrial reactive oxygen species (mROS) in response to S. 16 
pneumoniae and how this influenced intracellular bacterial killing. Some of the results 17 
of these studies have been previously reported in the form of an abstract (16). 18 
 19 
Materials and Methods. 20 
Bacteria and Infection 21 
Serotype 2 S. pneumoniae (D39 strain, NCTC 7466) , serotype 1 S. pneumoniae (WHO 22 
reference laboratory strain SSISP 1/1: Statens Seruminstitut), used in murine 23 
experiments (9) and  serotype 14 S. pneumoniae (NCTC11902) used in COPD 24 
 6 
experiments were cultured and opsonized in human (11) or murine serum before 1 
infection of cells as previously described  (13).  2 
Isolation and culture of macrophages  3 
Bone marrow-derived macrophages (BMDM) were obtained as described (9). Human 4 
monocyte-derived macrophages (MDM) were isolated from whole blood donated by 5 
healthy volunteers with written informed consent, as approved by the South Sheffield 6 
Regional Ethics Committee (11). AM from patients with  COPD (enrolled through MRC 7 
COPD-MAP) or from healthy controls (online data supplement Table E1) were isolated 8 
from BAL as previously described (16), with written approved consent prior to inclusion 9 
in the study as approved by the National Research Ethics Service Committee for 10 
Yorkshire and the Humber. Further information can be found in the online supplement.  11 
 12 
Western blot 13 
Whole cell extracts were isolated using SDS-lysis buffer and separated by SDS gel 14 
electrophoresis. Detailed information can be found in the online supplement.  15 
 16 
Immunohistochemistry  17 
Preparation of healthy and COPD lung sections (online data supplement Table E2), 18 
immunostaining and semi-quantitative evaluation, are described in the online 19 
supplement. 20 
 21 
Flow Cytometry 22 
Caspase activity was measured using the CellEvent caspase 3/7 green flow kit (Life 23 
Technologies), according to the manufacturers instructions. Mitochondrial reactive 24 
 7 
oxygen species (mROS) were measured by flow cytometry using the dye MitoSOX-Red 1 
(Invitrogen). Detailed information can be found in the online supplement.  2 
 3 
Microscopy 4 
Nuclear fragmentation and condensation indicative of apoptosis were detected using 5 
ƍƍ-diamidino-2-phenylindole (DAPI) (11). To visualise mROS cells were stained with 6 
2PM MitoSOX-red (Invitrogen) and visualized on a Leica DMRB 1000, 40x objective. 7 
For co-localisation experiments, lysosomes were stained with 0.50µM Cresyl violet 8 
(Sigma) or challenged with D39 labelled with Alexa Fluor 647 carboxylic acid 9 
succinimidyl ester (Life Technologies) and co-stained with MitoSOX-red for 15 min, 10 
and visualised by confocal microscopy (Zeiss LSM 510, 63x1.4 oil objective). In other 11 
experiments, MDM and BMDM were challenged with D39 labelled with Alexa Fluor 12 
647 and 16 h post-challenge cells were stained with MitoSOX and visualised by 13 
structured illumination microscopy (SIM). Detailed information can be found in the 14 
online supplement.  15 
 16 
Intracellular killing assay. 17 
Assessment of intracellular bacterial viability was carried out by gentamicin protection 18 
assay as previously described (17).   19 
 20 
Metabolic measurements 21 
Measurement of oxygen consumption rate (OCR) and extracellular acidification rate 22 
(ECAR) were performed using the XF24 extracellular flux analyser (Seahorse, 23 
Bioscience). Additional information can be found in the online supplement. 24 
 25 
 8 
In vivo infections 1 
Mcl-1 transgenic mice and wild-type littermates were infected and analyzed as outlined 2 
in the online supplement. Animal experiments were conducted in accordance with the 3 
Home Office Animals (Scientific Procedures) Act of 1986, authorized under UK Home 4 
Office License 40/3251 with approval of the Sheffield Ethical Review Committee, 5 
Sheffield, United Kingdom. 6 
 7 
Statistics 8 
Data are represented as mean and standard error unless otherwise indicated in the figure 9 
legends. Sample sizes were informed by standard errors obtained from similar assays in 10 
prior publications (12, 13). Analysis was performed with tests, as outlined in the figure 11 
legends, using Prism 6.0 software (GraphPad Inc.) and significance defined as p <0.05. 12 
Decisions on the use of parametric (for normally distributed data) or non-parametric 13 
tests (for non-normally distributed data) were informed by the distribution  of data. 14 
 15 
Results 16 
Mcl-1 is upregulated and is associated with reduced intracellular bacterial killing in 17 
COPD AM. 18 
The Bcl-2 family member Mcl-1 regulates both macrophage viability (18) and delayed 19 
bacterial killing through induction of apoptosis during exposure to bacteria such as the 20 
pneumococcus (12, 13). We therefore investigated whether Mcl-1 expression was 21 
altered in AM by COPD. These experiments were conducted with a strain of S. 22 
pneumoniae that frequently colonizes this patient group and which also can cause IPD 23 
(19). Since macrophages from patients with COPD have an impaired capacity to ingest 24 
bacteria (14, 15), we modified the inoculum presented to control human AM to 25 
 9 
normalize intracellular bacterial numbers (supplemental Figure E1) and demonstrated 1 
significant reduction in Mcl-1 expression LQ KHDOWK\ GRQRU¶V $0 but no reduction in 2 
expression in COPD AM after bacterial challenge (Figure 1A).  We also examined 3 
whether there was increased Mcl-1 expression in AM in the COPD lung. As illustrated 4 
quantification revealed enhanced Mcl-1 expression in lung biopsies of patients with 5 
COPD compared to control donors without COPD, which showed a focal distribution of 6 
high intensity (Figure 1B-D). The level of expression in controls was not altered by 7 
whether these were current smokers or non-smokers and results were similar when 8 
expression was analysed either by individual cell expression (Figure 1C) or by donor 9 
overall (Figure 1D).  10 
 11 
We next addressed whether COPD AM had any defects in early microbicidal responses.  12 
In keeping with prior reports with MDM (14),  we documented reduced phagocytosis of 13 
pneumococci by COPD AM (Figure 2A). Of note there was no evidence of the normal 14 
opsonic uplift in phagocytosis of pneumococci in COPD AM (16) in contrast to those 15 
from healthy donors.  Despite differences in initial internalization of opsonized bacteria 16 
and COPD there was no evidence of significant reduction in early intracellular bacterial 17 
killing, which is linked to initial bacterial phagocytosis in myeloid cells and reactive 18 
oxygen species (ROS) generation via nicotinamide adenine dinucleotide phosphate-19 
oxidase (20). To exclude confounding effects of differential bacterial internalization we 20 
adjusted the MOI used to challenge control AM, ensuring normalization of initial 21 
internalization (supplemental Figure E1), since apoptosis is directly related to initial 22 
bacterial ingestion (11). Upregulation of Mcl-1 was associated with reduced apoptosis in 23 
COPD AM (Figure 2B) and with enhanced survival of intracellular bacteria at a later 24 
time point (Figure 2C), supporting a defect in delayed apoptosis-associated 25 
pneumococcal killing by AM (12, 13).   26 
 10 
 1 
Mcl-1 upregulation in AM impairs bacterial clearance in the lung. 2 
CD68.hMcl-1+ transgenic mice were used to explore the functional consequence of Mcl-3 
1 upregulation for bacterial clearance and the putative association of Mcl-1 upregulation 4 
with altered intracellular bacterial clearance in COPD AM.  Expression of a human Mcl-5 
1 transgene in myeloid cell populations extends macrophage survival while ensuring 6 
cells remain sensitive to physiological constraints on viability so that there is normal 7 
distribution of myeloid subsets and development (21). Using a low dose of 8 
pneumococci, which AM are able to contain (9), we demonstrate that the presence of the 9 
macrophage transgene results in impaired bacterial clearance from the lung and also 10 
increased bacteremia (Figure 3A-B). These changes were found in association with 11 
reduced AM apoptosis (Figure 3C) and increased numbers of neutrophils in the 12 
broncholalveolar lavage fluid (BAL) (Figure 3D). 13 
 14 
Mcl-1 modulates generation of mitochondrial ROS and mROS-dependent bacterial 15 
killing. 16 
We next explored the links between induction of the Mcl-1 regulated apoptotic program 17 
and microbicidal responses, using BMDM as a model of differentiated macrophages. 18 
Mcl-1 regulates apoptosis at the level of the mitochondrion (12, 13) and mitochondrial 19 
ROS (mROS) has emerged as an important microbicidal strategy used by macrophages 20 
(22). mROS was significantly increased in CD68.hMcl-1-  BMDM (but not CD68.hMcl-21 
1+)  20h after bacterial challenge, with significantly lower levels in CD68.hMcl-1+ 22 
compared to CD68.hMcl-1- BMDM (Figure 4A-B). mROS co-localized with 23 
phagolysosomes and with bacteria, in contrast to endoplasmic reticulum, used as a 24 
control, which did not co-localize with either bacteria or phagolysosomes (Figure 4C-F 25 
and supplemental Figure E2-3). mROS staining was inhibited by an inhibitor 26 
 11 
mitoTEMPO and each stain provided minimal background signal (supplemental Figure 1 
E2-4). mROS co-localization with bacteria was also visible in human MDM (Figure 4E 2 
and supplemental Figure E2F-G).  mitoTEMPO, blocked the delayed phase of 3 
pneumococcal killing in CD68.hMcl-1- (but not CD68.hMcl-1+) BMDM (Figure 4G) 4 
and also in MDM (Figure 4H).  5 
 6 
Mcl-1 modulates mitochondrial oxidative phosphorylation in macrophages. 7 
Generation of mROS occurs during oxidative phosphorylation when electron leak 8 
predominantly from complex I results in generation of superoxide (23). We examined 9 
whether Mcl-1 modulates oxidative metabolism. As anticipated pneumococcal infection 10 
enhanced glycolytic metabolism (Figure 5A), in keeping with the known enhancement 11 
of glycolytic metabolism during macrophage responses to bacteria (24), but the 12 
CD68.hMcl-1 transgene did not alter glycolytic metabolism after infection.  Also as 13 
expected infection was associated with a reduction in several parameters associated with 14 
oxidative phosphorylation, but the transgene itself resulted in increased baseline and 15 
maximal oxygen consumption rate (OCR) in mock infected cells, though it had no effect 16 
on the levels after pneumococcal challenge (Figure 5B-F). In association with alterations 17 
in OCR parameters the transgene was also associated with increased baseline mROS 18 
levels in mock-infected cells (Figure 5G). Since caspase activation enhances mROS 19 
production through interference with complex I of the electron transport chain (25), we 20 
next tested if Mcl-1 inhibited the inducible mROS expression observed after 21 
pneumococcal challenge in a caspase-dependent process and whether this overwhelmed 22 
Mcl-¶V EDVHOLQH HIIHFWV RQ oxidative phosphorylation. As shown in Figure 5H-I, we 23 
show that Mcl-1 overexpression inhibits the increase in mROS production following 24 
bacterial challenge. Mcl-1 also specifically reduced the mROS production due to 25 
caspase activation after bacterial challenge, as treatment with the casapse inhibitor 26 
 12 
zVAD reduced MitoSOX levels to comparable levels to those of the Mcl-1 transgenic. 1 
In these experiments with zVAD and zFA the baseline level of mROS was lower than in 2 
the experiments in Figure 5G, reflecting reduced sensitivity of detection in the presence 3 
of these chemicals, and the baseline alteration in mROS production due to the transgene 4 
was no longer apparent. 5 
 6 
COPD AM fail to increase mROS production after pneumococcal challenge 7 
Since COPD patients had enhanced expression of Mcl-1 in AM (Figure 1 A-C), 8 
phenocopying the CD68.hMcl-1+ BMDM we next addressed whether they also had 9 
modulation of mROS generation in response to pneumococci and whether this 10 
influenced intracellular bacterial killing. AM from patients with COPD had enhanced 11 
levels of mROS at baseline and no increment with infection (Figure 6A). Inhibition of 12 
mROS in COPD AM did not increase intracellular bacterial numbers, suggesting mROS 13 
plays little role in bacterial killing in COPD AM (Figure 6B). COPD is associated with 14 
enhanced antioxidant expression as an adaptation to chronic production of ROS (26). 15 
The major antioxidant against superoxide in AM that is localized to mitochondria is 16 
manganese superoxide dismutase (MnSOD/SOD2) (27). AM from COPD patients had 17 
enhanced expression of SOD2 at baseline and maintained expression following bacterial 18 
challenge (Figure 6C). Thus, when we calculated a ratio of the change in mROS to 19 
SOD2 as a marker of mitochondrial oxidant/antioxidant balance, there was a significant 20 
increase in this ratio following infection in healthy but not COPD AM (Figure 6D). To 21 
test whether increased mROS reconstituted bacterial killing in COPD AM, we added the 22 
mitochondrial complex I inhibitor rotenone, which enhances mROS production (28), 23 
confirming it enhanced bacterial killing in both healthy and COPD AM (Figure  6E). In 24 
keeping with a limited role for mROS in induction of apoptosis under these 25 
circumstances, and the well developed resistance of AM to oxidative stress (29), we 26 
 13 
found that rotenone resulted in only a limited increase in AM apoptosis. Once again this 1 
suggested mROS was an effector of bacterial killing downstream of apoptosis rather 2 
than a stimulus for apoptosis induction (Figure 6F). 3 
 4 
 5 
Discussion 6 
 We demonstrate that COPD AM possess a specific defect in the delayed phase of 7 
intracellular bacterial killing in association with impairment of mROS generation. This 8 
phase of bacterial killing is regulated by the anti-apoptotic protein Mcl-1 (12, 13) and 9 
we provide evidence that Mcl-1 is upregulated in COPD AM. Using a novel transgenic 10 
mouse line in which human Mcl-1 is governed by the CD68 promoter we show that 11 
overexpression of Mcl-1 results in a reduction of bacterial clearance from the murine 12 
lung and that mROS is both required for the delayed phase of clearance and regulated 13 
via Mcl-1 expression. Mcl-1 enhances the oxygen consumption rate during oxidative 14 
phosphorylation and mROS production in mock-infected macrophages but during 15 
infection its major effect is to regulate caspase dependent mROS production. COPD AM 16 
have both high basal mROS generation and a failure to enhance mROS production after 17 
pneumococcal challenge, which results in decreased bacterial killing.  18 
 19 
 COPD is characterized by bacterial persistence in the airway and by enhanced rates of 20 
CAP and IPD (8, 30). Bacterial load in the airway correlates with progressive airway 21 
obstruction and maintenance of neutrophilic inflammation (5). Moreover, a recent 22 
murine model, involving polymeric immunoglobulin deficient mice, has demonstrated 23 
that persistent exposure to lung bacteria drive inflammatory changes and lung 24 
remodelling in the small airways (31). This suggests that innate immune dysfunction and 25 
 14 
impaired handling of respiratory pathogens is a central feature of COPD pathogenesis. 1 
In line with these observations several groups have demonstrated that COPD AM have 2 
altered activation states (32, 33) cytokine responses (34) and phagocytic capacity (15, 3 
35, 36). Despite this there has been little investigation of microbicidal responses in 4 
COPD AM. Moreover prior studies have varied in the extent to which they identify a 5 
systemic versus a local alveolar macrophage defect. Although confounding effects of 6 
smoking and corticosteroids are important considerations we had low rates of current 7 
smokers in the main patient group studied and although corticosteroid inhaler use was 8 
more frequent in the COPD group the patients studied by histochemistry contained very 9 
few who used corticosteroid inhalers, arguing against a major confounding effect of 10 
these on Mcl-1 expression.  11 
 12 
AM require additional microbicidal mechanisms to compliment early phagolysosomal 13 
bacterial killing since they lack myeloperoxidase (37) and the granule-associated serine 14 
proteases found in neutrophils (29). Moreover differentiated macrophages continue to 15 
phagocytose bacteria after conventional phagolysosomal microbicidal strategies are 16 
exhausted (38). Respiratory pathogens also express genes enabling their resistance to 17 
microbicidals (10). AM respond by activating a delayed phase of intracellular killing to 18 
diverse pathogens ranging from pneumococci to Mycobacterium tuberculosis (12, 13, 19 
39). Generation of mROS has emerged as an important microbicidal strategy used by 20 
macrophages (22) and its production is increased by caspase 3 mediated inhibition of 21 
complex I (25). Therefore it is well positioned to link induction of apoptosis to bacterial 22 
killing. In light of observations that bacteria such as pneumococci have adaptions to 23 
withstand oxidative stress, it is likely that mROS reacts to form other more potent 24 
microbicidals, such as reactive nitrogen species, to mediate bacterial killing (10). Our 25 
 15 
results suggest that this critical microbicidal strategy functions ineffectively in COPD 1 
AM. 2 
 3 
Mitochondrial function emerges as a key determinant of the COPD AM microbicidal 4 
response.  In COPD there is increasing evidence of mitochondrial dysfunction involving 5 
airway smooth muscle cells and skeletal muscle (40, 41). Enhanced mROS production is 6 
well described and is believed to contribute to COPD pathogenesis by contributing to 7 
the overall oxidative stress, promoting senescence and inflammation. The impact of 8 
mitochondrial dysfunction on macrophage innate immune responses is less appreciated 9 
but our data suggests that an additional consequence is impaired macrophage 10 
microbicidal responses. These are likely to be compounded further by impaired 11 
generation of classical macrophage activation in COPD (32, 33). Failure to generate 12 
classical activation, will reduce succinate generation an important driver of acute mROS 13 
production, required for microbicidal responses (42, 43), while the chronic production of 14 
mROS can favour alternative activation with consequences to innate immune responses 15 
(44). Upregulation of anti-oxidant defences, such as SOD2, in COPD (26), will further 16 
compromise mitochondrial microbicidal capacity. Our results suggest AM adaptions to 17 
chronic mROS generation will compromise the ability to generate an acute microbicidal 18 
response with mROS in the phagolysosome.  19 
 20 
The molecular regulation of mROS production involves Mcl-1. CD68.hMcl-1+ transgene 21 
expression increased markers of oxidative phosphorylation and mROS generation in 22 
mock-infected macrophages so its upregulation could theoretically drive chronic mROS 23 
production in COPD AM. The production of mROS is, however, influenced by more 24 
than the basal and maximal oxygen consumption rate and we do not know how COPD 25 
influences hydrogen ion leak and the function of uncoupling proteins in AM in COPD 26 
 16 
(23). Mcl-1 can exist as a form that localizes to the outer mitochondrial membrane and 1 
regulates apoptosis and another form that localizes to the mitochondrial matrix and 2 
enhances oxidative phosphorylation, while limiting mROS generation (45). This 3 
suggests that if Mcl-1 is to contribute to enhanced mROS expression in COPD AM 4 
either the expression of the matrix localized form must be altered or there are additional 5 
factors modulating proton leak to result in greater mROS production. An additional 6 
implication of this is that the reduced induction of mROS we document following 7 
pneumococcal challenge in association with maintenance of Mcl-1 expression may not 8 
just be a consequence of reduced caspase activation (and therefore inhibition of complex 9 
I (25)) but may also result from preservation of the matrix localized form of Mcl-1 (45). 10 
Regardless of these considerations there is still potential to overwhelm Mcl-1 in COPD 11 
AM and re-engage both induction of mROS and microbicidal capacity, as evidenced by 12 
the capacity of a complex I inhibitor to enhance bacterial clearance.  13 
 14 
Our findings have been based exclusively on experiments with the pneumococcus but 15 
are likely to have broad impact in COPD even though other bacteria such as non-16 
typeable H. influenzae are frequently implicated as colonizers of the COPD airway and 17 
drive inflammation (46). Pneumococci are the second most frequently bacterial 18 
colonizer in the lower airway in patients with COPD (46). They are likely to exert both 19 
direct effects on the frequency of COPD exacerbations and decline in FEV1; 20 
colonization with a monoculture of pneumococci specifically increased the risk of acute 21 
exacerbation in one study (19), but also indirect effects since there is evidence that 22 
pneumococcal colonization can promote H. influenzae or M. catarrhalis growth in the 23 
upper airway or promote mixed H. influenzae and S. pneumoniae biofilms (47, 48). 24 
They can also synergize with H. influenzae to promote pro-inflammatory cytokine 25 
responses in epithelial cells (49).  In addition they are the leading cause of CAP in 26 
 17 
patients with COPD (7). However the induction of apoptosis-associated bacterial killing 1 
is important against a range of pathogens (10), and the specific defect in mitochondrial 2 
microbicidal responses is therefore likely to have consequences for other pathogens in 3 
COPD beyond its effect on pneumococci.  4 
 5 
Although several defects in innate immune function have been identified in COPD the 6 
identification of a critical defect in the late phase of mitochondrial microbicidal killing 7 
in COPD AM represents a new therapeutic target. Manipulation of mitochondrial 8 
homeostasis, metabolism, or inhibition of Mcl-1, all represent potential approaches by 9 
which this critical defect could be modified. 10 
 11 
 12 
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Figure Legends 2 
Figure 1: Mcl-1 upregulation occurs in chronic obstructive pulmonary disease 3 
(COPD).  (A) Alveolar macrophages (AM) obtained from bronchoalveolar lavage of 4 
healthy controls or COPD patients were mock-infected (MI) or challenged with 5 
opsonized serotype 14 Streptococcus pneumoniae (S14) at the designated multiplicity 6 
of infection (MOI). 16h post-challenge the levels of Mcl-1 on AM were probed by 7 
western blot. A representative blot and densitometry are shown, n=6, *= p<0.05, 8 
repeated measures 1-way ANOVA. (B-C) Lung sections from COPD patients or 9 
healthy controls were dual stained with CD68 and Mcl-1. Total corrected cellular 10 
fluorescence (TCCF) of Mcl-1 in CD68 +ve cells was quantified. Representative 11 
images (B) and collated data (C and D) are shown. In C each point represents an 12 
individual cell (n=74 healthy, n=90 COPD, from 10 donors) and in D, each point 13 
represents the median fluorescence of all cells analysed from individual donors. For C 14 
and D, *= p<0.05, Kruskal-Wallis test.  15 
 16 
Figure 2: COPD alveolar macrophages have a deficiency in apoptosis-associated 17 
killing.  (A) Alveolar macrophages (AM) were collected from healthy donors or patients 18 
with COPD and were challenged with non opsonized (-) or opsonized (+) serotype 14 S. 19 
pneumoniae at an MOI of 10 for 4h, before extracellular bacteria were killed and viable 20 
intracellular bacteria measured. Viable bacteria in duplicate wells were measured again 21 
three hours later (7h post-infection), *= p<0.05. **= p<0.01, 2-way ANOVA.  (B-C) 22 
Healthy or COPD AM were challenged with S14, at an MOI of 10 for COPD cells, or 23 
MOI 5 for healthy cells, so as to normalize levels of bacterial internalization. Cells were 24 
analysed for (B) nuclear fragmentation or condensation and (C) intracellular bacterial 25 
 24 
colony forming units (CFU) at 20h post-challenge n=5-6, *= p<0.05, Students t-test (for 1 
B) or Mann-Whitney U test (for C).  2 
 3 
Figure 3: Mcl-1 upregulation in AM impairs bacterial clearance in the lung. 4 
 (A-D) Wild-type (Wt) or CD68.hMcl-1 transgenic (Tg) mice were challenged with 104 5 
serotype 1 Streptococcus pneumoniae. At the designated time after instillation, bacterial 6 
colony forming units (CFU) in the lung homogenate (A), CFU in the blood (B), alveolar 7 
macrophage (AM) nuclear fragmentation or condensation in bronchoalveolar lavage 8 
(BAL) (C) and total polymorphonuclear leukocyte (PMN) numbers in BAL (D) were 9 
measured. n=4-11 mice per group from three independent experiments,  *= p<0.05 **= 10 
p<0.01, 2-way ANOVA. 11 
 12 
Figure 4: Mcl-1 modulates generation of mitochondrial ROS and mROS-dependent 13 
bacterial killing. (A) Wild-type (Wt) or CD68.hMcl-1 transgenic (Tg) bone marrow-14 
derived (BMDM) were mock-infected (MI) or challenged with opsonized serotype 2 15 
(D39) S. pneumoniae. 20 h post-challenge cells were stained with MitoSOX and 16 
visualised by microscopy to assess mitochondrial reactive oxygen species (mROS) 17 
JHQHUDWLRQ ,PDJHV UHSUHVHQWDWLYH RI WKUHH LQGHSHQGHQW H[SHULPHQWV VFDOH EDU  ȝ018 
(B) At the designated time post-challenge, mROS were also assessed by flow cytometry, 19 
n=3 *= p<0.05 D39 Wt vs. D39 Tg, 2-way ANOVA. (C) MI or D39 infected Wt 20 
BMDM were stained with Cresyl violet to detect lysosomes (green) and MitoSOX (red) 21 
at 20 h and analysed by confocal microscopy. Co-localized signals are yellow (Merge), 22 
scale bar 5 ȝm. (D) Confocal fluorescence microscopy of D39 BMDM challenged with 23 
Alexa Fluor 647 labelled bacteria (green) and stained with MitoSOX (red, 4D upper 24 
panels) or endoplasmic reticulum (ER) tracker (purple, 4D, lower panel) 20h after 25 
bacterial challenge. Co-localized signals are yellow (Merge, 4D upper and lower panels, 26 
 25 
6FDOHEDUȝP). (E) Pseudo-coloured structured illumination microscopy (SIM) image 1 
of a monocyte-derived macrophage 16 h after bacterial challenge with S. pneumoniae 2 
(green) and stained with MitoSOX for mROS (red). Enlarged region on right shows 3 
bacteria co-localized with mROS (arrows). 6FDOHEDUȝm. (F) 3HDUVRQ¶VFRUUHODWLRQ4 
coefficients were calculated for the co-localization of mROS or ER with D39 or 5 
lysosomes, mean ± SEM (n=4-8). (G-H) Wt or Tg BMDM (G) or human MDM (H) 6 
were challenged with D39, in the presence or absence (vehicle) of mitoTEMPO (mT). 7 
16 h post-challenge intracellular colony forming units (CFU) were assessed, n=5 (for G) 8 
and n=8 (for H), **= p<0.01, repeated measures 2-way ANOVA (for G), or Wilcoxon 9 
matched-pairs signed rank test (for H). 10 
 11 
Figure 5: Mcl-1 modulates mitochondrial responses leading to mitochondrial 12 
reactive oxygen species generation. (A-F) Wild-type (Wt) or CD68.hMcl-1 transgenic 13 
(Tg) bone marrow-derived (BMDM) were mock-infected (MI) or challenged with 14 
opsonized serotype 2  (D39) S. pneumoniae for 4h before extracellular acidification 15 
(ECAR) (A) and parameters related to oxidative phosphorylation were measured 16 
kinetically. From the kinetic data (B), basal rates of oxygen consumption (OCR) (C), 17 
maximum respiration capacity (D), ATP linked OCR (E), and proton leak (F) were 18 
calculated, n=6 per group, *= p<0.05 **= p<0.01, 2-way ANOVA.  (G) Mock-infected 19 
Wt and Tg BMDM were stained with MitoSox to measure baseline mROS production. 20 
(H-I) Wt or Tg BMDM (H) or human monocyte-derived macrophages (MDM) (I) were 21 
MI or challenged with D39, in the presence of the pan-caspase inhibitor zVAD or 22 
control zFA. At 20h post-challenge, cells were stained for mROS and caspase 3/7 23 
activity. MitoSox staining was assessed for the whole cell populations (histograms). 24 
Representative plots are shown, with collated data graphed, n=4 *= p<0.01, 2-way 25 
ANOVA (for H), or 1-way ANOVA (for I). 26 
 26 
 1 
Figure 6. COPD AM fail to increase mROS production after pneumococcal 2 
challenge. (A-B) Alveolar macrophages (AM) obtained from bronchoalveolar lavage 3 
(BAL) of healthy controls (Healthy) or COPD patients (COPD) were mock-infected 4 
(MI) or challenged with opsonized serotype 14 S. pneumoniae (S14), at an MOI of 10 5 
for COPD cells, or MOI 5 for healthy cells.  AM were left unstained (US) or stained 6 
with MitoSOX and mean fluorescence intensity (MFI) recorded at 16h, as a measure of 7 
mitochondrial reactive oxygen species (mROS), with representative plots shown and 8 
collated data graphed,  (A) and intracellular bacterial colony forming units  (CFU) were 9 
estimated in the presence or absence (vehicle) of mitoTEMPO (mT) (B) at 20h. Both 10 
n= 6, *= p<0.05, paired Students t-test (A) or Wilcoxon signed rank test (B). (C) AM 11 
from BAL of healthy controls or COPD patients were mock-infected (MI) or 12 
challenged with S14 at the designated multiplicity of infection (MOI). At 16h post-13 
challenge the levels of superoxide dismutase (SOD)2 in AM were probed by western 14 
blot. Representative blot and densitometry are shown, n=4. (D) The ratio of mROS to 15 
SOD2 induced by bacterial challenge was calculated for healthy and COPD AM, using 16 
the samples in (C), n=4, *= p<0.05, Students t-test.  (E-F) Healthy or COPD AM were 17 
MI or challenged with S14, in the presence (+) or absence (-) of rotenone to induce 18 
mROS. AM were assessed for intracellular bacterial CFU (E) and nuclear 19 
fragmentation or condensation (F) 20h post-challenge, n=3, *= p<0.05, Wilcoxon 20 
signed rank test. 21 
 22 
